Michael R. Megna - 10 Apr 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHIEF ACCOUNTING OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 10 Apr 2023
Net transactions value: -$12,370
Form type: 4
Filing time: 11 Apr 2023, 17:07:19 UTC
Previous filing: 03 Apr 2023
Next filing: 06 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+3,933	+39%		14,132	10 Apr 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$12,370	-1,155	-8.2%	$10.71	12,977	10 Apr 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	+3,933	+50%	$0.000000	11,797	10 Apr 2023	Class A Common Share	3,933		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.